Growth outcomes following recombinant human growth hormone therapy in Zhu–Tokita–Takenouchi–Kim syndrome
Shien Chen Lee, Yusef Muflihi, Zainaba Mohammed, Esther Kinning, Renuka P Dias · 2026
Read Growth outcomes following recombinant human growth hormone therapy in Zhu–Tokita–Takenouchi–Kim syndrome by Shien Chen Lee, Yusef Muflihi, Zainaba Mohammed, Esther Kinning, Renuka P Dias (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13579057.txt.
Description
Shien Chen Lee and co-authors report growth hormone care for a child with a rare gene syndrome in work dated 2026. The syndrome, called ZTTK, stems from faults in the SON gene and slows growth in many children. The girl in the report had very short stature, low muscle tone, and slow learning. Tests showed hormone levels in the normal range.
A watched trial of the hormone raised her growth speed by more than half in the first phase. Gains held over two years, and her height score rose step by step. Blood tests stayed normal and no side effects were seen. The team backs a watched one-year trial for such cases.
Catalog record
| CREATOR | Shien Chen Lee, Yusef Muflihi, Zainaba Mohammed, Esther Kinning, Renuka P Dias |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 18 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |